Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $122,441.16 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 6,499 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $18.84, for a total transaction of $122,441.16. Following the completion of the transaction, the chief executive officer owned 339,392 shares in the company, valued at $6,394,145.28. This trade represents a 1.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total transaction of $129,675.90.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Trading Down 2.0%

BCAX stock opened at $18.41 on Monday. The firm has a market cap of $1.01 billion, a PE ratio of -8.22 and a beta of -0.78. The stock has a 50-day moving average price of $16.98 and a 200-day moving average price of $16.34. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $20.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after acquiring an additional 4,585 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Invesco Ltd. raised its position in shares of Bicara Therapeutics by 20.6% during the fourth quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock worth $354,000 after purchasing an additional 3,595 shares during the period. VARCOV Co. acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $263,000. Finally, Virtus Investment Advisers LLC lifted its holdings in shares of Bicara Therapeutics by 46.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock worth $242,000 after purchasing an additional 4,560 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have weighed in on BCAX. Citigroup started coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $30.25.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.